AWM
SMMT icon

Avior Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Avior Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21
Closed -$86 – 3513
2024
Q1 		$86 Buy
+21
New +$83 ﹤0.01% 3249

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Avior Wealth Management's SMMT Position: Q2 2024 in Review

Avior Wealth Management sold out of Summit Therapeutics (SMMT) in Q2 2024, closing a stake of 21 shares — an estimated $86 sold.

Avior Wealth Management first reported a position in SMMT in Q1 2024 and held it in 1 quarter. The position peaked at $86 in Q1 2024. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

  • Avior Wealth Management reported no remaining Summit Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 21 Summit Therapeutics shares in Q2 2024, an estimated $86.
  • Avior Wealth Management first reported a position in Summit Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Summit Therapeutics position peaked at $86 in Q1 2024.
  • 123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.